INTRODUCTION
Emerging data indicate that the proteins of the contact activation system (CAS) [factor XII (FXII), high-molecular-weight kininogen, prekallikrein] influence thrombosis risk without effect on hemostasis, the cessation of bleeding. The CAS and its interacting kallikrein/kinin system (KKS; see a recent review characterizing these two proteolytic systems) are participants in modulating thrombosis risk in the intravascular compartment and also interact closely with the renin-angiotensin system (RAS) [1 & ]. Mice deficient of FXII ( f12 À/À ), highmolecular-weight kininogen (kgn1 À/À ), or prekallikrein (klkb1 À/À ) have a delayed thrombosis time in arterial injury models [2,3 && ,4]. Additionally, mice deficient in the bradykinin B2 receptor (B2R; bdkrb2 À/À ) in the KKS also have delayed thrombosis [5, 6] . However, mice deficient in prolylcarboxypeptidase ( prcp gt/gt ), a protein involved in prekallikrein activation, and the angiotensin-(1-7) receptor, Mas (Mas1 À/À ), of the RAS have shorter arterial thrombosis times [7, 8] . In all cases, the change in thrombosis risk in these knockout mice has no effect on hemostasis and bleeding risk. Recently, a novel general hypothesis for the initiation of thrombosis has been proposed suggesting that vessel wall injury occurs first leading to subsequent platelet thrombus formation [9, 10] . Although this model was developed as a means to understand tissue factor (TF)-thrombin actions in clot formation, it also serves as a guide to better understand how the proteins of the CAS/KKS, to be discussed below, influence thrombosis risk in physiologic states. The present review examines what is known about the mechanisms of how FXII, high-molecular-weight kininogen, and prekallikrein influence thrombosis risk using the data derived from study of murine deletion models. In doing so, several commonly used murine thrombosis models are interpreted as to how they induce vessel occlusion. Supporting proteins like the B2R, Mas receptor, and prolylcarboxypeptidase are discussed to clarify mechanism(s) for thrombosis risk alteration associated with CAS proteins. The overall message of this review is that the mechanisms for thrombosis risk reduction for CAS/KKS proteins extend beyond contact pathway activation via physiologic or pathophysiologic surfaces in the intravascular compartment. The CAS/ KKS interacts with additional pathways to modulate thrombosis risk, and further understandings of these pathways should lead to more precise antithrombotic treatments.
Factor XII
Since its discovery in 1955, FXII deficiency was recognized to prolong surface-activated blood coagulation assays without a clinical increase in bleeding or abnormal hemostasis. For five decades since discovery, most investigators dismissed FXII as unimportant. However, recognition that f12 À/À mice have delayed thrombosis on several murine models without an increase in bleeding has generated renewed interest in this enzyme [2] . FXII has the peculiar ability to bind to artificial surfaces, and in doing so, it changes shape such that its singlechain zymogen becomes a two-chain active enzyme (FXIIa). The mechanism of this phenomenon called 'autoactivation' is unknown. Recent studies suggest that via polyphosphates (polyPs), inorganic polymers of orthophosphate units linked by phosphoanhydride bonds, FXII, like single-chain urokinase, elaborate proteolytic activity for small molecule substrates, without becoming a two-chain enzyme [11 && ]. PolyP is present in all prokaryotes and eukaryotes and becomes available on cell lysis. Additionally, aggregated proteins, amyloid b-peptide 1-42, vessel wall collagen, and RNA and DNA extruded from dying cells or neutrophils in the active process of NETosis also serve as charged surfaces for FXII autoactivation [1 & ]. It is commonly believed that the mechanism by which FXII contributes to thrombus formation in vivo in pathophysiologic and, perhaps, physiologic states is through contact autoactivation on exposed biologic surfaces leading to factor XI activation and subsequent thrombin formation (contact activation thrombin generation) [1 & ]. Animal thrombosis studies show that FXII deficiency affords thrombosis protection in injury models that are believed to depend on the contact activation pathway. f12 À/À mice are protected from stroke induced by a silicon rubber-coated nylon monofilament injury-induced middle cerebral artery (MCA) [12] . It is important to recall that the first indication for biologic contact activation was the observation that bird plasma (now known to be deficient in FXII) did not have an electronegative thread-accelerated blood clotting like other animals' plasmas [13] . f12 À/À mice are protected from collagen-epinephrine and long-chain polyPinduced venous thromboembolism, constrictioninduced venous thrombosis, and a rat arteriovenous shunt model [ 16, 17] . Most investigators agree that artificial surface exposure is an initiating event for thrombosis in these models, although the physiochemical process of autoactivation of FXII in these models has not been demonstrated in vivo. f12 À/À mice also have delayed arterial thrombosis on ferric chloride and Rose Bengal-induced carotid artery thrombosis [18, 19] . Understanding the mechanism(s) for how FXII deficiency leads to thrombosis delay in these latter models is less clear. Both the ferric chloride and Rose Bengal thrombosis models elevate vessel reactive oxygen species. Although it is claimed that ferric chloride treatment physically disrupts endothelium interfering with adhesion mechanisms and exposing collagen, other data suggest that after ferric chloride or Rose Bengal treatment, the endothelium is physically intact [20, 21] . It is harder to make an argument that loss of FXII contact activation on the chemically altered endothelium allows for the thrombosis delay. To my knowledge today, there are no studies examining f12 À/À animals on the cremasteric artery laser injury model for thrombosis.
Are there potential other mechanisms by which FXII contributes to the constitutive nature of arterial thrombosis in the intravascular compartment? FXII deficient patients have decreased leukocyte migration into skin windows [22] . To the extent that leukocytes participate in venous and arterial thrombosis, reduced leukocyte function associated with FXII deficiency may additionally reduce thrombosis potential. Such a mechanism KEY POINTS FXII increases thrombin generation by contact activation on artificial medical technology surfaces.
Prekallikrein deficiency decreases thrombosis by inhibiting contact activation and stimulating the vascular RAS to reduce vessel wall TF.
Both FXII and prekallikrein or its related pathways are good targets to prevent thrombosis on artificial medical surfaces or the natural vessel wall, respectively. may be occurring in stroke where FXII deficiency is protective [23] . In addition to altering leukocyte function, FXII's absence reduces bradykinin formation and bradykinin's effect on leukocyte function through the bradykinin B1 receptor could be contributory [24, 25] . Finally, FXIIa has a direct role in fibrin stabilization and its loss may alter formed fibrin such that it is less resistant to fibrinolysis [26] .
Although to date there is no direct evidence in vivo of FXII autoactivation on an abnormal biologic surface promoting thrombosis, indirect evidence suggests that such may be occurring. The amyloid peptide amyloid b-peptide 42 that forms in Alzheimer's disease is a FXII contact activation surface [27] . Alzheimer's disease is associated with microvessel thrombosis, and patients with Alzheimer's disease have evidence in plasma of prior in-vivo activation of the CAS as indicated by increased circulating FXIIa and decreased FXII and C1 inhibitor levels [28, 29] . Also, Alzheimer's disease mice have evidence for prior activation of contact proteins, and amyloid b-peptide 42 peptide injected into wild-type mice induces in-vivo contact activation [28, 29] .
Independent of disease states, inhibition of contact activation may be the best means to prevent medical artificial surface activation of blood coagulation. Recent investigations show that a phage display-produced fragment antigen binding portion Fab 3F7 to the light chain of FXIIa provides antithrombosis protection in rabbits attached to an extracorporeal membrane oxygenator equivalent to unfractionated heparin but with less fibrin formation [30 && ]. The use of this unique Fab to FXIIa introduces a novel antithrombotic agent that has no influence on hemostasis [31] . In these animal study participants, activated coagulation time is not measurable, but there is no risk for bleeding. This animal study is the best showing that the mechanisms for thrombosis are separable from blood coagulation and hemostasis. The ability to inhibit contact activation-induced thrombosis by FXIIa inhibition also is supported by the use of a rHA-Infestin-4 in a rat model of ischemic stroke [32] . In this latter investigation, infarct area and brain edema formation are reduced with better neurologic scores in treated animals [32] . rHA-Infestin-4 also prevents occlusion of an arteriovenous shunt model in mice and rabbits [33] .
Inhibition of FXII contact activation also is an important mechanism for catheter-induced thrombosis [34] . The observations above on the effect of anti-FXIIa inhibitors on medical device thrombosis are applicable to commonly used catheterinduced thrombosis [34] . There is limited protection from catheter-induced thrombin generation with antifactor Xa (e.g., fondaparinux) and antifactor IIa (e.g., dabigatran) therapies [35, 36] . Enoxaparin affords better protection from catheter-associated thrombus formation than fondaparinux because some low-molecular-weight heparin chains are of sufficient length to forms stable enzyme-antithrombin complexes with FXIIa, factor XIa, and factor IXa. Unfractionated heparin provides the best protection for this reason [34] .
Thus, precise indications for FXIIa inhibition for thrombosis prevention are developing from the array of in-vivo studies in progress [37] . Most investigations suggest that FXIIa inhibition in animals results in reduced contact activation-induced thrombin generation ( Fig. 1 ), but this mechanism is harder to reconcile with the protection seen in f12 À/À mice in the Rose Bengal and ferric chloride injury models. As FXIIa inhibition does not influence hemostasis, its use is highly suited for thrombosis prevention with any implanted medical device or indwelling artificial surface such as catheters and stents. This population of patients is enormous, but its introduction into medical trials will be delayed by the cost of the agent and the appropriate inherent conservatism of the cardiopulmonary bypass community's comfort with the use of unfractionated heparin. However, there are some cautions for the use of FXIIa inhibitors. Loss of FXIIa is currently not known to influence TF-induced thrombosis, but there are insufficient studies addressing this question. Further, absent FXIIa may adversely influence the stability of formed fibrin. Also, it is not known what effect long-term FXII/FXIIa inhibition will have on its role as a promoter of cell growth, angiogenesis, and neutrophil function in wound healing and injury repair [38] .
High-molecular-weight kininogen
High-molecular-weight kininogen is a cofactor for plasma kallikrein's (KAL) activation of FXII and FXIIa's activation of factor XI. In plasma, almost all of plasma prekallikrein and factor XI circulate bound to high-molecular-weight kininogen. Highmolecular-weight kininogen functions as the endothelial cell receptor for prekallikrein and factor XI. It is also a substrate of FXIIa, plasma KAL, and factor XIa and results in the liberation of bradykinin from high-molecular-weight kininogen [1 have delayed thrombosis on the Rose Bengal model for carotid artery thrombosis [4] . On a ferric chloride carotid artery thrombosis assay, kgn1 À/À mice occlude faster in response to 5 and 7.5% ferric chloride compared with klkb1 À/À mice. These data suggest that the absence of high-molecular-weight kininogen affords less thrombosis protection than absence of prekallikrein [40] . To put this comment in perspective, klkb1 À/À mice appear less protected from 5 to 10% ferric chloride-induced carotid artery 
Antithrombotic potential of the contact activation and KKSs. The contact activation system consists of FXII autoactivating on surfaces (biologic or artificial) to form FXIIa that then reciprocally activates prekallikrein to form plasma KAL with amplification of activation of each zymogen. The system is accelerated by the presence of the cofactor to XII and prekallikrein activation, high-molecular-weight kininogen. Another serine protease, PRCP, also activates prekallikrein to KAL independent of factor XIIa. Formed factor XIIa also activates factor XI (XIa) leading to contact activation-induced thrombin generation. Deletion of FXII ( f12 À/À mice) or inhibition of FXIIa blocks contact activation-induced thrombin generation. FXII also has a multiprotein receptor system on endothelium that consists of urokinase plasminogen activator receptor (uPAR), gC1qR, and cytokeratin 1 that when stimulated induces cell proliferation and angiogenesis. High-molecular-weight kininogen binds to the same receptor system to block these functions of FXII. The KKS consists of formed plasma KAL by any mechanism (XIIa, PRCP) cleaving high-molecular-weight kininogen to liberate bradykinin. Bradykinin binds to its constitutively expressed receptor, the B2R. In klkb1 À/À mice, reduced bradykinin formation and B2R expression is associated with increased amounts of the G-protein-coupled receptor Mas. Similarly, but to a greater extent, in B2R-deleted (bdkrb2 À/À ) mice, the absent receptor is associated with increased expression of the G-protein-coupled receptors Mas and AT2R. Further, it has elevated bradykinin that is metabolized by ACE of the renin-angiotensin system to produce bradykinin-(1-5) (RPPGF). The increased ACE activity also produces more AngII from angiotensin I. The excess AngII binds the AT2R or is metabolized by PRCP or ACE2 (not shown) to Ang-(1-7) to stimulate the Mas receptor. Ang-(1-7) is the natural ligand of Mas. The combined AngII and Ang-(1-7) agonism on the AT2R and Mas, respectively, results in a two-fold to three-fold increase in prostacyclin. In klkb1 À/À mice, constitutive levels of Ang-(1-7) are sufficient to stimulate the overexpressed Mas receptor to increase prostacyclin production 1.5-fold to two-fold. The increased prostacyclin in both animal models then leads to a cascade of downstream signals that first result in reduction of vessel wall tissue factor in addition to reduced contact activation. ACE, angiotensinconverting enzyme; Ang II, angiotensin II; Ang-(1-7), angiotensin-(1-7); AT2R, angiotensin receptor 2; B2R, bradykinin B2 receptor; FXII, factor XII, KAL, kallikrein; KKS, kallikrein/kinin system; klkb1 À/À , prekallikrein-deficient mice; PRCP, prolylcarboxypeptidase.
thrombosis than f12 À/À mice [40] . Thus, on the ferric chloride assay, loss of FXII provides the largest protection from thrombosis, followed by loss of prekallikrein, and high-molecular-weight kininogen-deficiency affords the least protection in the ferric chloride model -with the caveat that this model may not be an ideal assessment of contact activation-mediated thrombosis.
However, comparative inhibition studies are not investigations of the fundamental mechanistic basis for thrombosis protection. The kgn1 À/À mice have been studied the least regarding their mechanism(s) for thrombosis delay. kgn1 À/À mice are protected from stroke induced by nylon filament injury of the MCA -a model that appears to be a contact activation pathway-mediated thrombosis [41] . In a prostate cancer prostasome-induced model for pulmonary embolism, kgn1 À/À mice, like f12 À/À and f11 À/À mice, are resistant to pulmonary emboli and have a high rate of survival [15 & ]. Prostate cancer prostasomes are a form of polyP and its intravenous injection is considered a contact activation model resulting in acute pulmonary embolism, inflammation, and death [3 && ,14]. These results are distinctly different than that seen with klkb1 À/À , bdkrb2 À/À , and wild-type mice where the deficient proteins confer no protection from polyP-induced pulmonary embolism and death [3
These results confirm prior studies where klkb1 À/À mice, unlike f12 À/À mice, are not protected from long-chain polyP or collagen-epinephrine-induced pulmonary embolism and death [3 && ]. In sum, these studies suggest that the mechanism(s) by which high-molecular-weight kininogen deficiency contributes to thrombosis delay are more like those for f12 À/À mice than those involved in klkb1 À/À mice (see Prekallikrein). This assessment suggests that kininogen deficiency influences in-vivo contact activation potential and its contribution to thrombin generation similar to FXII and factor XI deficiency. Additional studies are needed to ascertain if highmolecular-weight kininogen deficiency has any effect on leukocyte function and influences the constitutive antithrombotic nature of the vessel wall like prekallikrein loss [3 && ,22]. Currently, too little is known about the mechanism(s) for thrombosis delay in high-molecular-weight kininogen deficiency in experimental studies to suggest it as a target for development of antithrombosis therapies.
Prekallikrein
Using the silicon rubber-coated nylon monofilament occlusion model in the MCA, klkb1 À/À mice are protected from transient brain ischemia [42] . Reconstitution of the klkb1 À/À with purified plasma prekallikrein such that the plasma levels of bradykinin were normalized restores their thrombotic potential to normal. These data are consistent with the findings of f12 À/À and kgn1 À/À mice and indicate that the mechanism that decreases ischemia in klkb1 À/À mice in the transient MCA brain ischemia model is reduced contact activation-induced thrombin generation [12, [41] [42] [43] . Prekallikrein deficiency is associated with reduced contact activation of plasma, but if one lets plasma sit on the bench for 3 h, the contact activation deficiency self corrects [44] . Prekallikrein increases the rate of contact activation but is not absolutely required for it like FXII. These data also are good evidence that the transient ischemia model MCA occlusion is basically a contact activation-induced thrombosis model. Additionally, prekallikrein deficiency is recognized to have delayed arterial thrombosis on ferric chloride and Rose Bengal assays [3 && ,43]. However, when the standard silicon rubbercoated nylon monofilament is permanently left in the MCA of klkb1 À/À mice, these animals are also protected from stroke [42] . These data are significantly different from those of permanent monofilament MCA occlusion experiments in f12 À/À and kgn1 À/À mice which are not protected [12, 41] . This observation suggests that another mechanism is occurring for thrombosis inhibition. This observation also supports the epidemiologic data that prekallikrein has an additional role in accelerating cardiovascular disease [45] [46] [47] . Several recent epidemiologic studies indicate that prekallikrein contributes to cardiovascular disease especially in diabetics [45] [46] [47] . The mechanism(s) by which prekallikrein contributes to stroke protection is not completely known but it may be related to an influence of prekallikrein on leukocyte function [42] . klkb1 À/À mice have reduced leukocyte migration and IL-1b mRNA in ischemic cerebral cortex and these parameters are corrected by reconstitution with plasma prekallikrein [42] . Rebuck [22] observed that klkb1 À/À patients have reduced leukocyte migration into skin windows. The influence of prekallikrein on brain parenchyma may be unique; however, because when we examined those observations extensively in skin wound biopsies and thioglycolate-induced peritoneal exudates, we did not see reduced leukocyte migration in klkb1 À/À mice tissue. As a result, we too sought other mechanisms to explain the constitutive, deleterious cardiovascular effects of prekallikrein and how its absence is thromboprotective.
As prekallikrein-deficient plasma in humans and mice has reduced contact activation-induced thrombin generation, we expected that the collagen-epinephrine or long-chain polyP-induced pulmonary embolism models in klkb1 À/À mice would yield results similar to those seen in f12 À/À mice [3 && ,43] . Surprisingly, we obtained opposite results [3 && ]. klkb1 À/À mice like wild-type mice have no protection from death in these models, unlike f12 À/À mice, despite inhibition of contact activation [3 && ,42] . In the collagen-epinephrine-induced pulmonary embolism model, klkb1 À/À mice have significantly less pulmonary edema as seen by Evans blue staining [3 && ]. There was no survival advantage or reduced thrombi for klkb1 À/À mice like wild-type mice and unlike f12 À/À mice. These data suggest several things. First, prekallikrein deficiency influences thrombosis risk differently than FXII deficiency. In support of that assessment, we observed that reconstitution of klkb1 À/À mice such that their plasma concentration of prekallikrein was 450 nmol/l does not correct the delayed time to thrombosis in the Rose Bengal thrombosis assay unlike the MCA occlusion model [3 && ,42] . Second, it also suggests that the collagen-epinephrine pulmonary embolism model may not be completely a contact activation-induced thrombosis model. Last, it suggests that FXII nulls may reduce thrombosis risk by mechanisms in addition to contact activation inhibition, but different from prekallikrein deficiency.
Investigations to find if prekallikrein influences thrombosis risk by mechanisms in addition to contact activation inhibition revealed that klkb1 À/À mice have a 1.5-fold to two-fold increase in plasma prostacyclin [3 && ]. This elevation occurs as result of a reduced B2R activation because of less plasma bradykinin release with a concomitant increase in the expression of the endothelial cell receptor Mas [3 && ]. Increased endothelial cell and plasma prostacyclin results in the expression of two vasculoprotective transcription factors, Kruppel-like factor 4 (KLF4) in endothelium and sirtuin [silent mating type information regulation 2 homolog 1 (Sirt1)] in vascular smooth muscle. Both KLF4 and Sirt1 act to dampen nuclear factor kappa-light-chain-enhancer of activated B cells function downregulating vascular TF expression [3 && ]. Plasma from klkb1 À/À mice has significantly reduced TF-induced thrombin generation that becomes particularly manifest at low dose (0.6 pM) TF concentrations [3 && ]. Further TF activity and antigen are reduced in the vessel wall [3 && ]. These data indicate that unlike f12 À/À and, perhaps, kgn1 À/À mice, klkb1 À/À have reduced thrombosis because of less vessel wall TF. These studies indicate that in prekallikrein deficiency, the major mechanism for thrombosis delay may be because of the reduction of vessel wall TF-induced thrombin generation (Fig. 1) . This mechanism for thrombosis protection in klkb1 À/À mice is an in-vivo example of the recent novel hypothesis that vessel wall TF and thrombin generation are the initial events in thrombus formation leading to platelet recruitment [9, 10] .
The thrombosis reduction mechanism seen in klkb1 À/À mice is not unique to this knockout animal alone. bdkrb2 À/À mice have a similar mechanism for thrombosis delay [5, 6] . In the absence of the B2R, both Mas and the angiotensin receptor 2 become increased. These animals have elevated prostacyclin and endogenous nitrate formation. Unlike klkb1 À/À mice, bdkrb2 À/À mice have long tail bleeding times that lead to a selective platelet function defect [6] . The platelet function defect is in part mediated by decreased collagen-induced platelet activation via glycoprotein VI and integrins a 2 b 1 [6] . bdkrb2 À/À mice have normal thrombin and ADP-induced platelet activation. The difference between klkb1 À/À and bdkrb2 À/À mice is the degree in elevation of plasma prostacyclin. klkb1 À/À mice have a 1.5-fold to two-fold increase in prostacyclin that alters vessel wall TF but is not high enough to inhibit platelets [3 && ]. bdkrb2 À/À mice, on the other hand, have a twofold to three-fold increase in plasma prostacyclin that reduces both vessel wall TF and collageninduced platelet activation [3 && ,6] . Like klkb1 À/À mice, bdkrb2 À/À mice have elevated vessel wall KLF4 and Sirt1 and reduced TF-induced thrombin generation of plasma [5, 6] .
The mechanism for thrombosis delay in klkb1 À/À mice is the mirror image of the thrombotic state in cyclooxygenase 2 deleted (COX2 À/À ) mice that have decreased prostacyclin, Sirt1, elevated vessel wall TF, and accelerated thrombosis [48] . Like COX2 À/À mice, Mas1 À/À and angiotensin receptor 2 null (agtr2 À/À ) mice have shortened times to arterial thrombosis [8, 48, 49] . Finally, prekallikrein is a zymogen that becomes activated to plasma KAL by FXIIa through the process of contact activation and by the endothelial cell S28 membrane serine protease prolylcarboxypeptidase (PRCP) independent of FXIIa [50, 51] . In endothelium, prolylcarboxypeptidase acts as a growth factor, stimulates angiogenesis, and promotes vascular repair [52] . Prcp gt/gt mice have increased vascular reactive oxygen species formation associated with constitutive hypertension and shortened times to arterial thrombosis [7, 53] . Prcp gt/gt mice have a cardiovascular thrombosis phenotype that is opposite to klkb1 À/À mice. These data suggest that the influence of prekallikrein on thrombosis is more complex than FXII. In the brain MCA transient wire placement model, reduced contact activation appears to be the mechanism for stroke reduction. In the Rose Bengal and ferric chloride carotid artery models, reduced vessel wall TF is the major pathway for thrombosis reduction. This latter mechanism involves interactions with receptors in the vascular RAS. Although plasma KAL inhibitors (such as ecallantide) have been useful in the management of acute attacks of hereditary angioedema, to my knowledge, we do not know if these agents also decrease thrombosis risk. The complexity of prekallikrein's actions suggests that its downstream targets may be best to modulate for thrombosis reduction than plasma prekallikrein itself.
CONCLUSION
There has been a significant increase in understandings of the contributions and importance of the proteins of the CAS and KKS. These proteins, FXII, high-molecular-weight kininogen, and prekallikrein, all reduce thrombosis risk without effect on hemostasis. Currently, there are good data to recommend targeting FXIIa for thrombosis reduction under conditions when human blood interfaces with medical artificial surfaces. More information is needed to determine if FXII/FXIIa inhibitors are effective antithrombosis agents in other conditions. Plasma prekallikrein deficiency prevents thrombosis through both inhibition of contact activation and reduction of vessel wall TF expression. This bimodal mechanism broadens the potential of prekallikrein inhibition even though compared with FXII deletion it is a less potent inhibitor in certain models such as the ferric chloride thrombosis assay. Further investigations may find analogous noncontact activation thrombosis inhibition pathways for FXII and highmolecular-weight kininogen. Additionally, targets mediating the delayed thrombosis of klkb1 À/À mice also may be viable antithrombosis agents. In sum, the CAS and KKS pathways have matured in understanding and may turn out to be important targets for new antithrombotic therapies. After 50 years, the unimportant proteins of the CAS have become very important with great therapeutic potential.
